Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Viola

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Endocrine-Related Cancer|May 22, 2016
Treatment of advanced thyroid cancer with targeted therapies: ten years of experienceDavid Viola, Laura Valerio, Eleonora Molinaro, et al.
Cancers|November 13, 2021
Active Surveillance in <i>RET</i> Gene Carriers Belonging to Families with Multiple Endocrine NeoplasiaAlessandro Prete, Antonio Matrone, Carla Gambale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2017
Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid CancerXiaopei Shen, Guangwu Zhu, Rengyun Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinomaKyeong J Kim, Sin G Kim, Jie Tan, et al.
Journal of the National Cancer Institute|November 23, 2017
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision TreatmentYueye Huang, Shen Qu, Guangwu Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2018
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerFei Wang, Shihua Zhao, Xiaopei Shen, et al.
The Journal of Clinical Endocrinology and Metabolism|July 17, 2021
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid CancerYubing Tao, Fei Wang, Xiaopei Shen, et al.
The Journal of Clinical Endocrinology and Metabolism|June 6, 2017
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid CancerFei Wang, Xiaolong Yu, Xiaopei Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Association between BRAF V600E mutation and recurrence of papillary thyroid cancerMingzhao Xing, Ali S Alzahrani, Kathryn A Carson, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Endocrine-Related Cancer|May 22, 2016
Treatment of advanced thyroid cancer with targeted therapies: ten years of experienceDavid Viola, Laura Valerio, Eleonora Molinaro, et al.
Cancers|November 13, 2021
Active Surveillance in <i>RET</i> Gene Carriers Belonging to Families with Multiple Endocrine NeoplasiaAlessandro Prete, Antonio Matrone, Carla Gambale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2017
Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid CancerXiaopei Shen, Guangwu Zhu, Rengyun Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinomaKyeong J Kim, Sin G Kim, Jie Tan, et al.
Journal of the National Cancer Institute|November 23, 2017
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision TreatmentYueye Huang, Shen Qu, Guangwu Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2018
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerFei Wang, Shihua Zhao, Xiaopei Shen, et al.
The Journal of Clinical Endocrinology and Metabolism|July 17, 2021
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid CancerYubing Tao, Fei Wang, Xiaopei Shen, et al.
The Journal of Clinical Endocrinology and Metabolism|June 6, 2017
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid CancerFei Wang, Xiaolong Yu, Xiaopei Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Association between BRAF V600E mutation and recurrence of papillary thyroid cancerMingzhao Xing, Ali S Alzahrani, Kathryn A Carson, et al.
Pageof 6